Extended Use of Histrelin Implant in Pediatric Patients.

Pine-Twaddell E, Newfield RS, Marinkovic M

Transgender health1 Jun 2023Cited by 11 (Europe PMC)

PMID37342480PMCIDPMC10278025DOI10.1089/trgh.2021.0130PepBankPUB-37342480

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

01HumanObservational studyEfficacy outcome
In pediatric patients, 42/50 histrelin implants maintained clinical/biochemical suppression throughout the study.
In plain wordsIn pediatric patients, 42/50 histrelin implants maintained puberty suppression throughout the study.
Peptide
Histrelin
Outcome
Not applicableMaintained pubertal suppression
Study
n = 49
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
Dose not stated
Measurements
Implants maintaining suppression
42 implants
histrelin
Source sentences
Summary
Most implants (42/50) maintained clinical/biochemical suppression for the duration of the study.
1 context sentence(design, population, supporting numbers)
Summary · context
This retrospective, two-center study included 49 subjects with 50 HI retained ≥17 months, in TG/NB (42) and CPP (7).
Report a problemFND-3734248001
02HumanObservational studyEfficacy outcome
Eight pediatric subjects escaped histrelin suppression at an average 30.4 months: five biochemical, two clinical, and one both.
In plain wordsEight pediatric patients lost histrelin puberty suppression after an average of 30.4 months: five biochemical, two clinical, and one both.
Peptide
Histrelin
Outcome
Not applicableEscape from pubertal suppression
Study
n = 49
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
Dose not stated
Measurements
Subjects with suppression escape
8 subjects
TG/NB and CPP subjects with retained implants
Average time to escape from placement
30.4 months
subjects with suppression escape
Escape, biochemical only
5 subjects
subjects with suppression escape
Escape, clinical only
2 subjects
subjects with suppression escape
Escape, clinical and biochemical
1 subjects
subjects with suppression escape
Source sentences
Summary
Pubertal suppression escape occurred in eight subjects at average 30.4 months from placement: five had only biochemical; two clinical; and one both clinical and biochemical escape.
1 context sentence(design, population, supporting numbers)
Summary · context
This retrospective, two-center study included 49 subjects with 50 HI retained ≥17 months, in TG/NB (42) and CPP (7).
Report a problemFND-3734248003
03HumanObservational studySafety outcome
In pediatric patients, 3/23 removed histrelin implants had breakage or difficult removal after an average 32.9 months.
In plain wordsIn pediatric patients, 3/23 removed histrelin implants had breakage or difficult removal after an average 32.9 months.
Peptide
Histrelin
Outcome
Not applicableImplant removal adverse effects
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated
Measurements
Removed implants with adverse effects
3 implants
implants removed (broken, difficult removal)
Implants removed
23 implants
denominator reported for adverse effects
Average time to removal
32.9 months
implants removed
Source sentences
Summary
After an average of 32.9 months, only 3/23 HI removed had adverse effects (HI broken, difficult removal).
1 context sentence(design, population, supporting numbers)
Summary · context
This retrospective, two-center study included 49 subjects with 50 HI retained ≥17 months, in TG/NB (42) and CPP (7).
Report a problemFND-3734248004

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.